Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Nymox Pharmaceutical Corporation is a biopharmaceutical company that focuses on the research and development of products primarily aimed at treating age-related medical conditions. The company's flagship product candidate is designed to treat benign prostatic hyperplasia (BPH), a condition that affects many older men. Nymox's mission is to improve the quality of life for patients by offering innovative therapeutic solutions that address significant unmet medical needs in the aging population. With its headquarters in Nassau, Bahamas, Nymox has been at the forefront of pharmaceuticals targeting prostate health, Alzheimer’s disease, and other areas impacting aging societies. The corporation's prominent focus and commitment to developing safe and effective treatments contribute significantly to healthcare advancements and opportunities within the global pharmaceutical market.
$0.00
+$0.00 (+0.00%)
Price from 2 days ago
Negative free cash flow of -$3M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$4M
▲ +49.2% YoY
Op. Margin
—
ROIC
—
Cash Flow & Balance Sheet
FCF (TTM)
-$3M
▲ +35.9% YoY
Op. Cash Flow (TTM)
-$3M
▲ +35.9% YoY
Net Debt
-$74K
Net Cash Position
Cash & Equiv.
$74K
Continue Research
Nymox Pharmaceutical (NYMXF)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Nymox Pharmaceutical scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Nymox Pharmaceutical scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 3 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh NYMXF's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.